Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 2/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15913578 | 0.96 | HCAR2 (0.35) | HCAR2PPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL15913355 | 0.95 | HCAR2 (0.34) | HCAR2PPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL20262465 | 0.90 | ATM (0.43) | HCAR2ALDH1A1NPSR1SMN1; SMN2HPGD | |
| SCHEMBL20601871 | 0.90 | GRIK1 (0.37) | HCAR2PPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL15913701 | 0.86 | ATM (0.43) | HCAR2ALDH1A1HPGDTSHR | |
| SCHEMBL20262516 | 0.85 | NPSR1 (0.47) | ALDH1A1NPSR1GLO1SMN1; SMN2GAA | |
| SCHEMBL15914179 | 0.85 | ATM (0.42) | HCAR2ALDH1A1SMN1; SMN2TP53HPGD | |
| SCHEMBL15913663 | 0.81 | NPSR1 (0.47) | ALDH1A1NPSR1GLO1SMN1; SMN2GAA | |
| SCHEMBL15913874 | 0.81 | PPM1B (0.33) | HCAR2PPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL28473155 | 0.81 | HCAR2 (0.34) | HCAR2PPM1BPTPN1PPP1CCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308563-B2 | Process for producing ethylene oligomers | HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) | 2019-06-04 | — | — | US | disclosed |
| CN-108212215-A | The catalyst system closed for ethylene oligomerization and the method using its production ethylene low polymer | 韩华道达尔有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-108218652-A | The method for producing ethylene low polymer | 韩华道达尔有限公司 | 2018-06-29 | — | — | CN | disclosed |
| US-20180169642-A1 | CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME | HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) | 2018-06-21 | — | — | US | disclosed |
| US-20180170827-A1 | PROCESS FOR PRODUCING ETHYLENE OLIGOMERS | HANWHA TOTALENERGIES PETROCHEMICAL CO., LTD. (KR) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308563-B2 | Process for producing ethylene oligomers | OXER1, HAO2, ORC3 | HCAR2 159/4885PPM1B 4279/4885PTPN1 4333/4885 |
| US-20180169642-A1 | CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME | HACL2, HAO2, MSMO1 | HCAR2 212/4885PPM1B 4507/4885PTPN1 4589/4885 |
| US-20180170827-A1 | PROCESS FOR PRODUCING ETHYLENE OLIGOMERS | OXER1, HAO2, ORC3 | HCAR2 159/4885PPM1B 4279/4885PTPN1 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.